> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Advisory Panel to Discuss Reata Pharma NDA
- URL: https://www.fdaweb.com/advisory-panel-to-discuss-reata-pharma-nda/
- Published: 2021-09-23T12:00:00.000Z
- Updated: 2026-09-14T17:15:59.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5150203

*Federal Register* notice: FDA has announced a 12/8 Cardiovascular and Renal Drugs Advisory Committee meeting. Panel members are scheduled to discuss a Reata Pharmaceuticals NDA for its Nrf2 activator bardoxolone methyl capsules, indicated for slowing chronic kidney disease progression caused by Alport syndrome in patients 12 years of age and older. To view the notice, click [here](https://public-inspection.federalregister.gov/2021-20733.pdf?ref=fdaweb.com).